Agios Pharmaceuticals (NASDAQ:AGIO) versus SAB Biotherapeutics (NASDAQ:SABS) Financial Contrast
by Tristan Rich · The Markets DailyAgios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Risk and Volatility
Agios Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Insider & Institutional Ownership
7.8% of SAB Biotherapeutics shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Agios Pharmaceuticals and SAB Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
| SAB Biotherapeutics | N/A | -6.74% | -6.06% |
Valuation & Earnings
This table compares Agios Pharmaceuticals and SAB Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $54.03 million | 35.14 | -$412.78 million | ($7.01) | -4.54 |
| SAB Biotherapeutics | $1.32 million | 205.42 | $13.27 million | ($1.30) | -2.29 |
SAB Biotherapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Agios Pharmaceuticals and SAB Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
| SAB Biotherapeutics | 1 | 1 | 9 | 0 | 2.73 |
Agios Pharmaceuticals presently has a consensus price target of $41.75, suggesting a potential upside of 31.29%. SAB Biotherapeutics has a consensus price target of $12.00, suggesting a potential upside of 302.68%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Agios Pharmaceuticals.
Summary
SAB Biotherapeutics beats Agios Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.